Radionuclide angiocardiographic evaluation of the cardiovascular effects of recombinant human IGF-I in normal adults | Zendy

G Bisi | Zendy; Valerio Podio | Zendy; MR Valetto | Zendy; Fabio Broglio | Zendy; Giovanni Bertuccio | Zendy; G. Del Rió | Zendy; M. Boghen | Zendy; F. Berti | Zendy; Müller Ee | Zendy; Ezio Ghigo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Radionuclide angiocardiographic evaluation of the cardiovascular effects of recombinant human IGF-I in normal adults

Author(s) -

G Bisi,

Valerio Podio,

MR Valetto,

Fabio Broglio,

Giovanni Bertuccio,

G. Del Rió,

M. Boghen,

F. Berti,

Müller Ee,

Ezio Ghigo

Publication year - 1999

Publication title -

european journal of endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 148

eISSN - 1479-683X

pISSN - 0804-4643

DOI - 10.1530/eje.0.1400322

Subject(s) - medicine , endocrinology , cardiac function curve , ejection fraction , basal (medicine) , inotrope , heart rate , blood pressure , insulin , heart failure

IGF-I possesses specific myocardial receptors and is able to promote cardiac remodelling and even inotropic effects in both humans and other animals. In fact, reduced cardiac mass and performance are present in GH deficiency and these alterations are counteracted by recombinant human (rh) GH replacement, restoring IGF-I levels. Recently, the acute administration of 60 microg/kg rhIGF-I has also been reported to be able to improve cardiac performance evaluated by echocardiography or impedance cardiography in normal subjects. The aim of our study was to verify the effects of a subcutaneous low dose of rhIGF-I (20 microg/kg) on cardiac performance in humans.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research